We are leaders in CRISPR/Cas9 gene targeting. We have completed over 100 CRISPR/Cas9 projects including knockouts, reporter and point mutant knockins and targeted transgenics. Our fees are low, our wait times are short and our success rates are high. New transgenic and targeted mice that we have created are featured in over 270 publications since 2004. We are supported by the Case Western Reserve University School of Medicine the Case Comprehensive Cancer Center, the Clinical and Translational Science Collaborative, the Research Institute for Children's Health and by grants from the NIH, the Cystic Fibrosis Foundation and JobsOhio.

We are a component of the FIND Pipeline, which translates gene-directed approaches into therapies for inherited disease.